Optimizing the dasatinib dose regimen in chronic phase chronic myeloid leukemia: 100 mg once daily available for use

Ravi Vij

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Optimizing the dasatinib dose regimen in chronic phase chronic myeloid leukemia: 100 mg once daily available for use'. Together they form a unique fingerprint.